Overview

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

Status:
Completed

Trial end date:
2020-01-30

Target enrollment:

Participant gender:

Summary

This phase I trial studies the best dose and side effects of trigriluzole in combination with nivolumab and pembrolizumab in treating patients with solid malignancies or lymphoma that has spread to other places in the body or cannot be removed by surgery. Trigriluzole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab and pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving trigriluzole in combination with nivolumab and pembrolizumab may work better at treating patients with solid malignancies or lymphoma.

Phase:

Phase 1

Details

Lead Sponsor:

Rutgers, The State University of New Jersey

Collaborator:

National Cancer Institute (NCI)

Treatments:

Antibodies, Monoclonal
Enzyme Inhibitors
Nivolumab
Pembrolizumab